Table 3.

SET_ER/PR for prediction of overall survival

	HR	95 % CI	p
Chemotherapy (N = 33)
SETER/PR	0.813	0.318−2.077	0.666
Endocrine treatment (N = 97)
SETER/PR	0.391	0.239−0.638	<0.001
Endocrine treatment and relapsed stage IV (N = 79)
SETER/PR	0.381	0.221−0.656	0.001
Endocrine treatment and relapsed stage IV
SETER/PR	0.315	0.157−0.631	0.001
PR status	0.524	0.267−1.029	0.061
Visc. met.	1.808	0.945−3.460	0.074
Event >2	4.463	1.943−10.25	<0.001
Prior Sens.	0.331	0.156−0.700	0.004
Endocrine treatment and relapsed stage IV and prior sensitivity (N = 46)
SETER/PR	0.316	0.154−0.649	0.002
Endocrine treatment and relapsed stage IV and prior sensitivity
SETER/PR	0.275	0.119−0.637	0.003
PR status	0.433	0.189−0.995	0.049
Visc. met.	1.827	0.785−4.250	0.162
Event >2	5.222	2.082−13.10	<0.001

Cox regression analyses for prediction of overall survival using the dichotomized SET_ER/PR. Results are shown for patients that received chemotherapy and those that received endocrine treatment. Uni- and multivariate analyses are shown for the clinically relevant subgroups of patients that received endocrine treatment and presented with relapsed stage IV disease and the subset of patients with a prior history of endocrine sensitivity

HR hazard ratio, CI confidence interval